View IGF-DES Certificate of Analysis
Why Choose IGF-1 DES?
IGF-1 DES, also known as des(1-3)IGF-I, is a naturally occurring truncated analogue of Insulin-like Growth Factor-1, lacking the N-terminal tripeptide Gly-Pro-Glu. This structural modification was identified in biological sources such as bovine colostrum, human brain, and porcine uterus . It was developed as a potent research tool for studying cellular growth and proliferation, distinguished by its enhanced bioavailability and significantly reduced affinity for IGF-binding proteins (IGFBPs) . Understanding its distinct origins and mechanisms provides important context for researchers.
The History & Origins
IGF-1 (Insulin-like Growth Factor-1), also known as Somatomedin C, is a key mediator of growth hormone’s anabolic effects, playing a fundamental role in mammalian growth and development . IGF-1 DES was first identified and characterized in the late 1980s as a naturally occurring variant, likely resulting from post-translational cleavage of the full-length peptide . It was isolated from human and bovine colostrum, human brain, porcine uterus, and other biological fluids, with evidence suggesting it may be produced by proteolytic cleavage of native IGF-1 at the N-terminus .
Initial research published in the Biochemical Journal in 1989 by Bagley and colleagues identified des(1-3)IGF-I as a highly potent analogue with significantly enhanced biological activity . Subsequent studies established its reduced affinity for IGFBPs as the key mechanism for this increased potency, leading to its widespread adoption as a research tool. The patent literature from the early 1990s further characterized its potential applications, describing it as “surprisingly” effective for enhancing growth in catabolic states and gut disorders . Since then, it has been widely studied in in vitro and preclinical models for its anabolic, metabolic, and tissue repair properties.
How They Work: Distinct Mechanisms
IGF-1 DES operates through a mechanism that is distinct from native IGF-1, primarily due to its engineered resistance to IGF-binding proteins.
Reduced IGFBP Binding: The Key to Enhanced Potency
In the body, IGF-1 is largely bound to a family of seven IGF-binding proteins (IGFBPs) that extend its half-life and control its access to tissues. IGF-1 DES has a dramatically reduced affinity for IGFBPs compared to native IGF-1 . This reduced binding has a key effect:
-
Increased Bioavailability: The peptide is more available to bind to the IGF-1 receptor (IGF-1R) because it is not sequestered by IGFBPs . This results in a 5- to 10-fold greater biological potency in cell culture and animal models, depending on the specific assay .
IGF-1 Receptor Activation
Despite its reduced IGFBP binding, IGF-1 DES retains high affinity for the type 1 IGF receptor (IGF-1R) . It binds to IGF-1R with comparable affinity to native IGF-1 . This activation promotes key signaling pathways—including the MAPK and PI3K cascades—which are fundamental to cell survival, proliferation, differentiation, and protein synthesis.
Anabolic and Metabolic Research
Preclinical studies have demonstrated IGF-1 DES’s potent effects in various research models:
-
Anabolic Effects: In dexamethasone-treated catabolic rat models, IGF-1 DES was approximately 2.5-fold more potent than native IGF-1 at promoting body weight gain and nitrogen retention .
-
Gastrointestinal Research: Studies in growth hormone-deficient mice and dexamethasone-treated rats demonstrated that IGF-1 DES significantly increased gut weight, mucosal growth, and villus height, suggesting potential applications in gut function research .
-
Muscle Protein Synthesis: Research has shown IGF-1 DES exerts coordinate anabolic effects on both muscle protein synthesis and breakdown .
-
Enhanced ED50: In a cell proliferation assay using human MCF-7 cells, the ED50 for IGF-1 DES is reported as less than 2 ng/ml, corresponding to a specific activity of >5.0 × 10⁵ IU/mg
